featured
No Risk of Breast or Gynecologic Malignancies in Women Treated With Spironolactone for Dermatologic Conditions
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study
J Am Acad Dermatol 2024 Jun 01;90(6)1302-1304, RC Hill, Y Wang, B Shaikh, SR LipnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.